Human Buccal Mucosa as an Innovative Site of Drug Delivery

Campisi, Giuseppina; Paderni, Carlo; Saccone, R.; Fede, Olga Di; Wolff, Ändy; Giannola, Libero Italo

doi:10.2174/138161210790883778

Cited by 68 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have investigated the delivery of a variety of drugs through the buccal mucosa in order to assess both local and systemic, either positive or adverse, effects. In conclusion, buccal mucosa might be considered a promising site for effective, safe and non-invasive transmucosal sustained drug delivery [31]. According to this hypothesis, interesting results have been obtained in an experimental model on the in vivo trasbuccal delivery of galantamine, a drug used for in AD therapy.…”

Section: Age-related Diseases and Therapeuticsmentioning

confidence: 90%

Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement

Candore

Caruso

Jirillo³

et al. 2010

CPD

123

View full text Add to dashboard Cite

Nowadays, people are living much longer than they used to do, however they are not free from ageing. Ageing, an inexorable intrinsic process that affects all cells, tissues, organs and individuals, is a post-maturational process that, due to a diminished homeostasis and increased organism frailty, causes a reduction of the response to environmental stimuli and, in general, is associated to an increased predisposition to illness and death. However, the high incidence of death due to infectious, cardiovascular and cancer diseases underlies a common feature in these pathologies that is represented by dysregulation of both instructive and innate immunity. Several studies show that a low-grade systemic inflammation characterizes ageing and that inflammatory markers are significant predictors of mortality in old humans. This pro-inflammatory status of the elderly underlies biological mechanisms responsible for physical function decline and agerelated diseases such as Alzheimer's disease and atherosclerosis are initiated or worsened by systemic inflammation. Understanding of the ageing process should have a prominent role in new strategies for extending the health old population. Accordingly, as extensively discussed in the review and in the accompanying related papers, investigating ageing pathophysiology, particularly disentangling agerelated low grade inflammation, is likely to provide important clues about how to develop drugs that can slow or delay ageing.

show abstract

Section: Age-related Diseases and Therapeuticsmentioning

confidence: 90%

Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement

Candore

Caruso

Jirillo³

et al. 2010

CPD

123

View full text Add to dashboard Cite

show abstract

“…The basement membrane with a thickness of about 1-2 m acts as barrier to permeability only marginally, limiting the diffusion of certain molecules (such as complexes) from and to the epithelium [19]. Furthermore, the surface charge of its molecules may impede and/or limit the penetration of lipophilic molecules which have just passed the epithelial layer relatively easily [20].…”

Section: Oral Mucosa: Histology Physiology and Permeability Featuresmentioning

confidence: 99%

Mucoadhesive Polymers for Oral Transmucosal Drug Delivery: A Review

Bagán¹,

Paderni²,

Termine³

et al. 2012

CPD

View full text Add to dashboard Cite

Abstract:The oral mucosa offers an interesting site for the application of dosage forms that release drugs within/throughout the oral mucosa, by assuring a high drug bioavailability for topic and systemic effects. However, the relative permeability of the oral mucosa and the washing effect related to the oral fluids and mechanical stresses must be considered in the formulation of oral dosage forms. Since a sustained drug release can be guaranteed only if dosage forms remain in contact with the oral site of absorption/application for a prolonged time, the development of mucoadhesive dosage forms is mandatory. The mucoadhesion is a complex phenomenon and the mucoadhesive bond consists of two different parts, the mucoadhesive polymers and the mucous substrate. In addition to factors related to the oral mucosa and oral environment features, the physical-chemical characteristics of mucoadhesive polymers must be also considered as factors influencing the mucoadhesive bonds. While it is not possible to modify the mucosal features or it is possible to modify or inhibit only in part certain mucosal processes, the knowledge of polymer properties influencing mucoadhesive bonds allows to modify or to control these properties in developing increasingly effective mucoadhesive systems. The aims of this review are to discuss the several mechanisms and factors behind the phenomenon of mucoadhesion with particular reference to the features of the oral environment, oral mucosa, and polymeric compounds influencing mucoadhesion process. Finally, a brief mention to the main mucoadhesive dosage forms designed for oral transmucosal drug delivery is made.

show abstract

“…Taking these benefits together buccal route of administration rendered beneficial and useful for a variety of drugs (Campisi et al, 2010). Buccal delivery involves the administration of the drug through the buccal mucosal membrane lining of the oral cavity (Kraan et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

In vitroevaluation of thio-poly acrylic acid for intraoral delivery

2015

View full text Add to dashboard Cite

Context: Intraoral drug delivery as mucosal delivery pathway provides a huge platform in the pharmaceutical field. Objective: Combining mucoadhesiveness and controlled release of thio-poly acrylic acid as advanced excipient for buccal drug delivery. Materials and methods: Mediated by carbodiimide, cysteine was covalently attached to poly acrylic acid. This thiomer was assessed with regard to cytotoxicity, stability, mucoadhesion, and rheology as well as release behavior of Lidocaine. Results: Stability assays of thio-poly acrylic acid were complying with United States Pharmacopeia requirements. Mucoadhesion assay such as tensile (total work of adhesion), bioadhesion, rotating cylinder revealed as this thiomer was superior in comparison to nonthiolated poly acrylic acid with 7.61-fold, 2.8-fold, 5.61-fold improvement, respectively without any toxic effect. The cell viability exhibited over 90% after incubation time of 3 h and 24 h respectively. Lidocaine release showed 1.98-fold more controlled release over 3 h in comparison to unmodified poly acrylic acid. Conclusion: Taken the findings in consideration, thio-poly acrylic acid provides excellent stability, controlled release, and superior mucoadhesive features. The prolonged residence time of thio-poly acrylic acid represents a pillar in the buccal drug delivery.

show abstract

Human Buccal Mucosa as an Innovative Site of Drug Delivery

Cited by 68 publications

References 0 publications

Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement

Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement

Mucoadhesive Polymers for Oral Transmucosal Drug Delivery: A Review

In vitroevaluation of thio-poly acrylic acid for intraoral delivery

Contact Info

Product

Resources

About